RCC Update from ESMO 2023

Prof. Laurence Albiges joined us at ESMO 2023 to share her views on the latest renal cell carcinoma (RCC) data presented at the congress. She reviewed data from the following studies:

• LBA87 - Phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
• LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomised open-label phase 3 LITESPARK-005 study
• 1881O - Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomised phase 2 LITESPARK-013 study
• 1882O - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomised, open-label, phase 3 study
• 1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
• 1884MO - Phase 2 study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study

Watch her video update and download the accompanying slides for a detailed summary.

Clinical Takeaways

• LITESPARK-003/005/013: belzutifan plus cabozantinib appears to improve outcomes in first and subsequent-line settings. Belzutifan monotherapy improves outcomes after IO or VEGFR TKI therapies in previously treated mRCC
• MEDI5752: Volrustomig monotherapy is active in treatment-naïve aRCC and has the potential to improve outcomes
• TIDE-A: Shows that VEGFR-TKI discontinuation is safe for selected mRCC patients with evidence of response to VEGFR-TKI+IO combinations in 1st line
• RENOTORCH: As a significant number of RCC patients live in China, the RENOTORCH trial is expected to be practice-changing for a large population of patients with advanced RCC worldwide